ObsEva appoints David Renas as Chief Financial Officer
Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the appointment of David Renas as Chief Financial Officer (CFO) and member of the company’s Executive Committee, effective today. He will be based in the U.S.
“David has demonstrated a track record of leadership and we are delighted to welcome him onto the executive team,” said Brian O’Callaghan, Chief Executive Officer of ObsEva. “I’m confident he will play a key role in further strengthening our relationships with investors and potential partners as we prepare to file a new drug application (NDA) in the U.S. in the first half of 2021 for Yselty, for the treatment of heavy menstrual bleeding and pain associated with uterine fibroids in pre-menopausal women, and further develop Ebopiprant for the treatment of pre-term labor following the recent release of our positive Ph II data.” “I would also like to thank our Chief Administrative Officer (CAO), Fabien de Ladonchamps, for the wonderful job he has done as interim CFO”.
David Renas joins ObsEva with more than 30 years of financial and legal experience, including 15 years within the pharmaceutical and life sciences industry. Most recently, he served as CFO at Petra Pharma and CFO and General Counsel at Sangart, where amongst other accomplishments he helped guide the company through 11 clinical trials conducted across 20 countries. David Renas also served as a Partner at Adkins Black LLP. Prior to focusing on the life sciences industry, he was an attorney in private practice with Gray Cary Ware & Freidenrich (now DLA Piper) and Foley & Lardner, and a CPA at Deloitte. David Renas holds a Bachelor of Arts in Economics from Stanford University and a Juris Doctorate from the University of California at Davis.
“I am thrilled to be joining as CFO at such an important time in the development of ObsEva which has recently submitted a Marketing Authorization Application (MAA) for its lead product Yselty for uterine fibroids to the European Medicines Agency (EMA) and has an anticipated NDA submission in 1H 2021. I look forward to working with the exceptional team on this exciting journey,” said David Renas.
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving embryo transfer outcomes following in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
Cautionary Note Regarding Forward Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates, and ObsEva’s plan to submit its MAA in Europe and NDA in the United States. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, clinical development and related interactions with regulators, , ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2019, the Risk Factors disclosed in ObsEva’s Report on Form 6-K filed with the Securities and Exchange Commission (SEC) on November 5, 2020 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
CEO Office contact
+41 22 552 1550
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
REPURCHASE OF SHARES20.1.2021 18:15:00 CET | Press release
REPURCHASE OF SHARES Amsterdam, the Netherlands - Flow Traders N.V. (“Flow Traders”) (Euronext: FLOW) has repurchased 62,790 of its own shares in the period from 14 January 2021 up to and including 20 January 2021 at an average price of €28.52. As announced on 11 November 2020, these repurchases are being made in order to satisfy the requirements of various employee incentive plans. The consideration of this purchase was €1.8 million. The total number of shares purchased under this programme to date is 799,922 shares at an average price of €26.90 for a total consideration of €21.5 million. 2,031,091 shares were held in treasury as at 20 January 2021. Contact Details Flow Traders N.V. Jonathan Berger / Investor Relations Officer Phone: +31 20 7996799 Email: firstname.lastname@example.org About Flow Traders Flow Traders is a leading global financial technology-enabled liquidity provider in financial products, historically specialized in Exchange Traded Products (ETPs), now expanding
KONNECT SELECTS SOLUTIONS 30 TO ROLL OUT ITS OFFER IN WESTERN EUROPE20.1.2021 18:00:00 CET | Press release
Solutions 30 (Euronext Paris: S30) has been selected by konnect, an entity of the Eutelsat Group (Euronext Paris: ETL), to roll out its new ultra high-speed satellite Internet access for the general public. As part of this partnership, Solutions 30 will carry out all installation services, allowing konnect to guarantee its customers a professional, uniform, and standardized installation in European countries where its offer is marketed. Europe’s leading provider of rapid-response multi-technology services, Solutions 30 performs more than 60,000 call-outs a day thanks to a team of 11,000 technicians and a particularly dense territorial network in Europe. For more than 15 years, the company has leveraged a unique software platform for team management and call-out optimization to provide customers with a standardized operating process that guarantees service quality and consistency. A significant part of Solutions 30’s business is in telecommunications, where it intervenes on behalf of th
Auction details government bonds20.1.2021 16:20:00 CET | Press release
Auction date January 27, 2021 Maturity date Loan ISIN code Coupon Issue volume, SEK million 2023-11-13 1057 SE0004869071 1.5% 1,5002031-05-12 1062 SE0013935319 0.125% 3,500 Settlement date January 29, 2021 Bids have to be entered by 11.00 on January 27, 2021 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 FO@riksgalden.se
SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING20.1.2021 16:20:00 CET | Press release
Bid date, 2021-01-22Bid Submission Date2021-01-22Bid times10.30-11.00 (CET/CEST) on the Bid dateOffered Amount50 billion SEKMaximum Permitted Bid Volume12.5 billion SEK from an individual bidderSettlement Date2021-01-26Minimum Permitted Bid Volume10 million SEK per bidFinal Repayment Date2025-01-27Maximum Allocation25 per cent of Offered AmountAllocation TimeNo later than 11.30 (CET/CEST) on the Bid dateRepayment Date2022-01-26Option Repayment Date 12023-01-26Option Repayment Date 22024-01-26Interest rateThe Riksbank´s applicable repo rateAdditional interest rate0.10 per centConfirmation of bids to email@example.com Stockholm, 2021-01-20 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes20.1.2021 16:07:55 CET | Press release
Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the US in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. The submission follows the application on 29 December 2020 for label extension to the European Medicines Agency (EMA). The submission is based on the results from the SUSTAIN FORTE trial, which included 961 people with type 2 diabetes in need of treatment intensification. In the trial, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c compared to semaglutide 1.0 mg. In the tria
ArcAroma AB: 210120 ArcAroma och OptiFreeze skapar tillsammans ett starkare bolag20.1.2021 16:00:00 CET | Pressemelding
Pressmeddelande 2021-01-20 ArcAroma och OptiFreeze skapar tillsammans ett starkare bolag Styrelserna i ArcAroma AB (publ) och OptiFreeze AB (publ) beslutade igår att föreslå ett samgående mellan bolagen genom fusion. Beslutet har tagits mot bakgrund av den marknadspotential och de synergieffekter som identifierats i samband med bolagens utökade samarbetsavtal, som tecknades i november 2020. ArcAroma och OptiFreeze har i olika omfattning samarbetat sedan grundandet av OptiFreeze 2011, där ArcAroma var en av grundarna till OptiFreeze. Sedan bolagens utökade samarbete inleddes i november 2020 har marknadsmöjligheter och synergier framstått som allt tydligare om bolagens resurser och tillväxtpotential kombineras. När fusionen är genomförd är målet att inleda processen för ett listbyte till Nasdaq Stockholm Small Cap. Storleken på det fusionerade bolaget skapar rätt förutsättningar för en kostnadseffektiv accelererad tillväxt som vilar på en unik teknologiplattform. Det nya bolagets kostnad
Equinor ASA: Early Warning Press Release20.1.2021 12:49:07 CET | Press release
Stavanger, Rogaland, Norway, January 20, 2021 – Equinor ASA ("Equinor") (OSE: EQNR, NYSE: EQNR) announces that on January 19, 2021 it disposed of its beneficial ownership of an aggregate of 100,000,000 common shares ("Common Shares") of Athabasca Oil Corporation ("Athabasca"), at a price of C$0.18 per Common Shares, for aggregate gross proceeds of C$18,000,000 (the "Transaction"), through the facilities of the Toronto Stock Exchange on a block trade basis. Immediately prior to the Transaction, Equinor beneficially owned and controlled a total of 100,000,000 Common Shares of Athabasca, representing approximately 18.8% of the issued and outstanding Common Shares of Athabasca. Immediately following the Transaction, Equinor no longer has beneficial ownership and control over any of the issued and outstanding Common Shares of Athabasca. As a result of the Transaction, Equinor's beneficial ownership of Common Shares of Athabasca has decreased to less than 10% of the issued and outstanding Co